Misplaced Pages

#791208

64-474: The Comparative Toxicogenomics Database (CTD) is a public website and research tool that curates scientific data describing relationships between chemicals, genes/proteins, diseases, taxa, phenotypes, GO annotations, pathways, and interaction modules, launched on November 12, 2004. The database is maintained by the Department of Biological Sciences at North Carolina State University. One of the primary goals of CTD

128-504: A compound hits, the more likely that off-target toxicity will occur with that compound once it reaches the clinic. It is unlikely that a perfect drug candidate will emerge from these early screening runs. One of the first steps is to screen for compounds that are unlikely to be developed into drugs; for example compounds that are hits in almost every assay, classified by medicinal chemists as " pan-assay interference compounds ", are removed at this stage, if they were not already removed from

192-475: A compound that fulfills all of these requirements has been identified, the process of drug development can continue. If successful, clinical trials are developed. Modern drug discovery is thus usually a capital-intensive process that involves large investments by pharmaceutical industry corporations as well as national governments (who provide grants and loan guarantees ). Despite advances in technology and understanding of biological systems, drug discovery

256-580: A drug is developed with evidence throughout its history of research to show it is safe and effective for the intended use in the United States, the company can file an application – the New Drug Application (NDA) – to have the drug commercialized and available for clinical application. NDA status enables the FDA to examine all submitted data on the drug to reach a decision on whether to approve or not approve

320-409: A drug, it has been suggested that natural products compare favourably to today's combinatorial chemistry libraries as potential lead molecules. Two main approaches exist for the finding of new bioactive chemical entities from natural sources. The first is sometimes referred to as random collection and screening of material, but the collection is far from random. Biological (often botanical) knowledge

384-487: A guide to improve the potency and properties of new drug leads. There is also a paradigm shift in the drug discovery community to shift away from HTS, which is expensive and may only cover limited chemical space , to the screening of smaller libraries (maximum a few thousand compounds). These include fragment-based lead discovery (FBDD) and protein-directed dynamic combinatorial chemistry . The ligands in these approaches are usually much smaller, and they bind to

448-423: A known physiological/pathological pathway, avoiding the mass screening of banks of stored compounds. This led to great success, such as the work of Gertrude Elion and George H. Hitchings on purine metabolism , the work of James Black on beta blockers and cimetidine , and the discovery of statins by Akira Endo . Another champion of the approach of developing chemical analogues of known active substances

512-491: A large chemical space when compared to HTS. Phenotypic screens have also provided new chemical starting points in drug discovery.   A variety of models have been used including yeast, zebrafish, worms, immortalized cell lines, primary cell lines, patient-derived cell lines and whole animal models. These screens are designed to find compounds which reverse a disease phenotype such as death, protein aggregation, mutant protein expression, or cell proliferation as examples in

576-536: A lead compound series has been established with sufficient target potency and selectivity and favourable drug-like properties, one or two compounds will then be proposed for drug development . The best of these is generally called the lead compound , while the other will be designated as the "backup". These decisions are generally supported by computational modelling innovations. Traditionally, many drugs and other chemicals with biological activity have been discovered by studying chemicals that organisms create to affect

640-458: A more holistic cell model or organism. Smaller screening sets are often used for these screens, especially when the models are expensive or time-consuming to run.   In many cases, the exact mechanism of action of hits from these screens is unknown and may require extensive target deconvolution experiments to ascertain. The growth of the field of chemoproteomics has provided numerous strategies to identify drug targets in these cases. Once

704-459: A new drug approval process, called the New Drug Application in the United States. Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws , regulatory exclusivity, marketing , and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected,

SECTION 10

#1733085285792

768-460: A particular disease usually involves high-throughput screening (HTS), wherein large libraries of chemicals are tested for their ability to modify the target. For example, if the target is a novel GPCR , compounds will be screened for their ability to inhibit or stimulate that receptor (see antagonist and agonist ): if the target is a protein kinase , the chemicals will be tested for their ability to inhibit that kinase. Another function of HTS

832-446: A process known as reverse pharmacology . Hits from these screens are then tested in cells and then in animals for efficacy . Modern drug discovery involves the identification of screening hits, medicinal chemistry , and optimization of those hits to increase the affinity , selectivity (to reduce the potential of side effects), efficacy/ potency , metabolic stability (to increase the half-life ), and oral bioavailability . Once

896-450: A target, are also often used. Another method for drug discovery is de novo drug design , in which a prediction is made of the sorts of chemicals that might (e.g.) fit into an active site of the target enzyme. For example, virtual screening and computer-aided drug design are often used to identify new chemical moieties that may interact with a target protein. Molecular modelling and molecular dynamics simulations can be used as

960-405: A target, in particular functional information. In general, "new targets" are all those targets that are not "established targets" but which have been or are the subject of drug discovery efforts. The majority of targets selected for drug discovery efforts are proteins, such as G-protein-coupled receptors (GPCRs) and protein kinases . The process of finding a new drug against a chosen target for

1024-456: Is a Japanese public-private effort which has published gene expression and pathology information for more than 170 compounds (mostly drugs). The Predictive Safety Testing Consortium aims to identify and clinically qualify safety biomarkers for regulatory use as part of the FDA 's "Critical Path Initiative". ToxCast is a program for Predicting Hazard, Characterizing Toxicity Pathways, and Prioritizing

1088-483: Is a commonly used method for novel drug discovery, it is not the only method. It is often possible to start from a molecule which already has some of the desired properties. Such a molecule might be extracted from a natural product or even be a drug on the market which could be improved upon (so-called "me too" drugs). Other methods, such as virtual high throughput screening , where screening is done using computer-generated models and attempting to "dock" virtual libraries to

1152-415: Is a good scientific understanding, supported by a lengthy publication history, of both how the target functions in normal physiology and how it is involved in human pathology. This does not imply that the mechanism of action of drugs that are thought to act through a particular established target is fully understood. Rather, "established" relates directly to the amount of background information available on

1216-596: Is a project hosted by the National Institute of Environmental Health Sciences building a knowledge base of toxicology studies including study design, clinical pathology, and histopathology and toxicogenomics data. InnoMed PredTox assesses the value of combining results from various omics technologies together with the results from more conventional toxicology methods in more informed decision-making in preclinical safety evaluation. Open TG-GATEs (Toxicogenomics Project-Genomics Assisted Toxicity Evaluation System)

1280-461: Is a subdiscipline of pharmacology that deals with the collection, interpretation, and storage of information about gene and protein activity within a particular cell or tissue of an organism in response to exposure to toxic substances . Toxicogenomics combines toxicology with genomics or other high-throughput molecular profiling technologies such as transcriptomics , proteomics and metabolomics . Toxicogenomics endeavors to elucidate

1344-402: Is broadly defined as the study of inter-individual variations in whole-genome or candidate gene single-nucleotide polymorphism maps, haplotype markers, and alterations in gene expression that might correlate with drug responses. Though the term toxicogenomics first appeared in the literature in 1999, it was by that time already in common use within the pharmaceutical industry as its origin

SECTION 20

#1733085285792

1408-415: Is hoped, the properties of the new molecular entities will improve, and allow the favoured compounds to go forward to in vitro and in vivo testing for activity in the disease model of choice. Amongst the physicochemical properties associated with drug absorption include ionization (pKa), and solubility; permeability can be determined by PAMPA and Caco-2 . PAMPA is attractive as an early screen due to

1472-408: Is known as reverse pharmacology and is the most frequently used approach today. In the 2020s, qubit and quantum computing started to be used to reduce the time needed to drug discovery. A "target" is produced within the pharmaceutical industry. Generally, the "target" is the naturally existing cellular or molecular structure involved in the pathology of interest where the drug-in-development

1536-444: Is meant to act. However, the distinction between a "new" and "established" target can be made without a full understanding of just what a "target" is. This distinction is typically made by pharmaceutical companies engaged in the discovery and development of therapeutics. In an estimate from 2011, 435 human genome products were identified as therapeutic drug targets of FDA-approved drugs. "Established targets" are those for which there

1600-640: Is now an option for drug developers. AI algorithms are being used to perform virtual screening of chemical compounds, which involves predicting the activity of a compound against a specific target. By using machine learning algorithms to analyse large amounts of chemical data, researchers can identify potential new drug candidates that are more likely to be effective against a specific disease. Algorithms, such as Nearest-Neighbour classifiers, RF, extreme learning machines, SVMs, and deep neural networks (DNNs), are used for VS based on synthesis feasibility and can also predict in vivo activity and toxicity. The elucidation of

1664-533: Is often used to identify families that show promise. This approach is effective because only a small part of the earth's biodiversity has ever been tested for pharmaceutical activity. Also, organisms living in a species-rich environment need to evolve defensive and competitive mechanisms to survive. Those mechanisms might be exploited in the development of beneficial drugs. A collection of plant, animal and microbial samples from rich ecosystems can potentially give rise to novel biological activities worth exploiting in

1728-554: Is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. In 2010, the research and development cost of each new molecular entity was about US$ 1.8 billion. In the 21st century, basic discovery research is funded primarily by governments and by philanthropic organizations, while late-stage development is funded primarily by pharmaceutical companies or venture capitalists. To be allowed to come to market, drugs must undergo several successful phases of clinical trials, and pass through

1792-495: Is to advance the understanding of the effects of environmental chemicals on human health on the genetic level, a field called toxicogenomics . The etiology of many chronic diseases involves interactions between environmental factors and genes that modulate important physiological processes. Chemicals are an important component of the environment. Conditions such as asthma , cancer, diabetes , hypertension , immunodeficiency , and Parkinson's disease are known to be influenced by

1856-425: Is to show how selective the compounds are for the chosen target, as one wants to find a molecule which will interfere with only the chosen target, but not other, related targets. To this end, other screening runs will be made to see whether the "hits" against the chosen target will interfere with other related targets – this is the process of cross-screening. Cross-screening is useful because the more unrelated targets

1920-535: Is used to study possible adverse (i.e. toxic ) effects of pharmaceutical drugs in defined model systems in order to draw conclusions on the toxic risk to patients or the environment. Both the United States Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) currently preclude basing regulatory decision-making on genomics data alone. However, they do encourage

1984-590: The 1000 Genomes Project individuals were assessed and associations with genetic markers were determined. Parts of this data were used in the NIEHS-NCATS-UNC DREAM Toxicogenetics Challenge in order to determine methods for cytotoxicity predictions for individuals. Drug discovery In the fields of medicine, biotechnology , and pharmacology , drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying

Comparative Toxicogenomics Database - Misplaced Pages Continue

2048-512: The anticoagulant drugs, hirudin and its synthetic congener , bivalirudin , are based on saliva chemistry of the leech , Hirudo medicinalis . Used to treat type 2 diabetes , exenatide was developed from saliva compounds of the Gila monster , a venomous lizard . Microbes compete for living space and nutrients. To survive in these conditions, many microbes have developed abilities to prevent competing species from proliferating. Microbes are

2112-414: The chemical space based on their physicochemical characteristics, is often used to describe the difference between the combinatorial chemistry libraries and natural products. The synthetic, combinatorial library compounds seem to cover only a limited and quite uniform chemical space, whereas existing drugs and particularly natural products, exhibit much greater chemical diversity, distributing more evenly to

2176-405: The orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances. The idea that the effect of a drug in the human body is mediated by specific interactions of the drug molecule with biological macromolecules, ( proteins or nucleic acids in most cases) led scientists to the conclusion that individual chemicals are required for

2240-669: The ECM. The discovery of JADs on skin repair has introduced newfound interest in the effects of these plant hormones in therapeutic medicinal application. Salicylic acid (SA), a phytohormone , was initially derived from willow bark and has since been identified in many species. It is an important player in plant immunity , although its role is still not fully understood by scientists. They are involved in disease and immunity responses in plant and animal tissues. They have salicylic acid binding proteins (SABPs) that have shown to affect multiple animal tissues. The first discovered medicinal properties of

2304-538: The Toxicity Testing of Environmental Chemicals at the United States Environmental Protection Agency . Tox21 is a federal collaboration involving the National Institutes of Health (NIH), Environmental Protection Agency (EPA), and Food and Drug Administration (FDA), is aimed at developing better toxicity assessment methods. Within this project the toxic effects of chemical compounds on cell lines derived from

2368-507: The ability to directly act on mitochondrial membranes by inducing membrane depolarization via release of metabolites . Jasmonate derivatives (JAD) are also important in wound response and tissue regeneration in plant cells. They have also been identified to have anti-aging effects on human epidermal layer. It is suspected that they interact with proteoglycans (PG) and glycosaminoglycan (GAG) polysaccharides , which are essential extracellular matrix (ECM) components to help remodel

2432-744: The above four data sets, CTD automatically constructs putative chemical-gene-phenotype-disease networks to illuminate molecular mechanisms underlying environmentally-influenced diseases. These inferred relationships are statistically scored and ranked and can be used by scientists and computational biologists to generate and verify testable hypotheses about toxicogenomic mechanisms and how they relate to human health. Users can search CTD to explore scientific data for chemicals, genes, diseases, or interactions between any of these three concepts. Currently, CTD integrates toxicogenomic data for vertebrates and invertebrates. CTD integrates data from or hyperlinks to these databases: Toxicogenomics Toxicogenomics

2496-665: The active ingredient from traditional remedies or by serendipitous discovery, as with penicillin . More recently, chemical libraries of synthetic small molecules , natural products , or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology . After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease-modifying in

2560-520: The activity of other organisms for survival. Despite the rise of combinatorial chemistry as an integral part of lead discovery process, natural products still play a major role as starting material for drug discovery. A 2007 report found that of the 974 small molecule new chemical entities developed between 1981 and 2006, 63% were natural derived or semisynthetic derivatives of natural products . For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs,

2624-401: The biological activity of the drug. This made for the beginning of the modern era in pharmacology , as pure chemicals, instead of crude extracts of medicinal plants , became the standard drugs. Examples of drug compounds isolated from crude preparations are morphine , the active agent in opium, and digoxin , a heart stimulant originating from Digitalis lanata . Organic chemistry also led to

Comparative Toxicogenomics Database - Misplaced Pages Continue

2688-448: The chemical library. It is often observed that several compounds are found to have some degree of activity , and if these compounds share common chemical features, one or more pharmacophores can then be developed. At this point, medicinal chemists will attempt to use structure–activity relationships (SAR) to improve certain features of the lead compound : This process will require several iterative screening runs, during which, it

2752-744: The chemical space. The most prominent differences between natural products and compounds in combinatorial chemistry libraries is the number of chiral centers (much higher in natural compounds), structure rigidity (higher in natural compounds) and number of aromatic moieties (higher in combinatorial chemistry libraries). Other chemical differences between these two groups include the nature of heteroatoms (O and N enriched in natural products, and S and halogen atoms more often present in synthetic compounds), as well as level of non-aromatic unsaturation (higher in natural products). As both structure rigidity and chirality are well-established factors in medicinal chemistry known to enhance compounds specificity and efficacy as

2816-420: The chemical structure is critical to avoid the re-discovery of a chemical agent that is already known for its structure and chemical activity. Mass spectrometry is a method in which individual compounds are identified based on their mass/charge ratio, after ionization. Chemical compounds exist in nature as mixtures, so the combination of liquid chromatography and mass spectrometry (LC-MS) is often used to separate

2880-467: The drug development process. One example of successful use of this strategy is the screening for antitumor agents by the National Cancer Institute , which started in the 1960s. Paclitaxel was identified from Pacific yew tree Taxus brevifolia . Paclitaxel showed anti-tumour activity by a previously undescribed mechanism (stabilization of microtubules) and is now approved for clinical use for

2944-406: The environment; however, the molecular mechanisms underlying these correlations are not well understood. CTD may help resolve these mechanisms. The most up-to-date extensive list of peer-reviewed scientific articles about CTD is available at their publications page CTD is a unique resource where biocurators read the scientific literature and manually curate four types of core data: By integrating

3008-410: The first immunosuppressant ( azathioprine ) that allowed human organ transplantation; the first drug to induce remission of childhood leukemia; pivotal anti-cancer treatments; an anti-malarial; an anti-bacterial; and a treatment for gout. Cloning of human proteins made possible the screening of large libraries of compounds against specific targets thought to be linked to specific diseases. This approach

3072-560: The first time that sugar moieties other than ribose and deoxyribose can yield bioactive nucleoside structures. It took until 2004 when the first marine-derived drug was approved. For example, the cone snail toxin ziconotide , also known as Prialt treats severe neuropathic pain. Several other marine-derived agents are now in clinical trials for indications such as cancer, anti-inflammatory use and pain. One class of these agents are bryostatin -like compounds, under investigation as anti-cancer therapy. As above mentioned, combinatorial chemistry

3136-430: The individual chemicals. Databases of mass spectra for known compounds are available and can be used to assign a structure to an unknown mass spectrum. Nuclear magnetic resonance spectroscopy is the primary technique for determining chemical structures of natural products. NMR yields information about individual hydrogen and carbon atoms in the structure, allowing detailed reconstruction of the molecule's architecture. When

3200-522: The isolated compound was involved in pain and fever management. They also play an active role in the suppression of cell proliferation. They have the ability to induce death in lymphoblastic leukemia and other human cancer cells. One of the most common drugs derived from salicylates is aspirin , also known as acetylsalicylic acid, with anti-inflammatory and anti-pyretic properties. Some drugs used in modern medicine have been discovered in animals or are based on compounds found in animals. For example,

3264-748: The low consumption of drug and the low cost compared to tests such as Caco-2, gastrointestinal tract (GIT) and Blood–brain barrier (BBB) with which there is a high correlation. A range of parameters can be used to assess the quality of a compound, or a series of compounds, as proposed in the Lipinski's Rule of Five . Such parameters include calculated properties such as cLogP to estimate lipophilicity, molecular weight , polar surface area and measured properties, such as potency, in-vitro measurement of enzymatic clearance etc. Some descriptors such as ligand efficiency (LE) and lipophilic efficiency (LiPE) combine such parameters to assess druglikeness . While HTS

SECTION 50

#1733085285792

3328-498: The main source of antimicrobial drugs. Streptomyces isolates have been such a valuable source of antibiotics, that they have been called medicinal molds. The classic example of an antibiotic discovered as a defense mechanism against another microbe is penicillin in bacterial cultures contaminated by Penicillium fungi in 1928. Marine environments are potential sources for new bioactive agents. Arabinose nucleosides discovered from marine invertebrates in 1950s, demonstrated for

3392-427: The molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns (i.e., molecular biomarkers ) that predict toxicity or the genetic susceptibility to it. In pharmaceutical research, toxicogenomics is defined as the study of the structure and function of the genome as it responds to adverse xenobiotic exposure. It is the toxicological subdiscipline of pharmacogenomics , which

3456-445: The numbers were higher. Natural products may be useful as a source of novel chemical structures for modern techniques of development of antibacterial therapies. Many secondary metabolites produced by plants have potential therapeutic medicinal properties. These secondary metabolites contain, bind to, and modify the function of proteins (receptors, enzymes, etc.). Consequently, plant derived natural products have often been used as

3520-564: The plant (e.g. roots, leaves, and flowers) are crucial for correctly identifying bioactive and pharmacological plant properties. Identifying new drugs and getting them approved for market has proved to be a stringent process due to regulations set by national drug regulatory agencies . Jasmonates are important in responses to injury and intracellular signals. They induce apoptosis and protein cascade via proteinase inhibitor , have defense functions, and regulate plant responses to different biotic and abiotic stresses . Jasmonates also have

3584-510: The starting point for drug discovery. Until the Renaissance , the vast majority of drugs in Western medicine were plant-derived extracts. This has resulted in a pool of information about the potential of plant species as important sources of starting materials for drug discovery. Botanical knowledge about different metabolites and hormones that are produced in different anatomical parts of

3648-498: The study of the general use of plants in society, and ethnopharmacology , an area inside ethnobotany, which is focused specifically on medicinal uses. Artemisinin , an antimalarial agent from sweet wormtree Artemisia annua , used in Chinese medicine since 200BC is one drug used as part of combination therapy for multiresistant Plasmodium falciparum . Additionally, since machine learning has become more advanced, virtual screening

3712-500: The synthesis of many of the natural products isolated from biological sources. Historically, substances, whether crude extracts or purified chemicals, were screened for biological activity without knowledge of the biological target . Only after an active substance was identified was an effort made to identify the target. This approach is known as classical pharmacology , forward pharmacology, or phenotypic drug discovery. Later, small molecules were synthesized to specifically target

3776-472: The target protein with weaker binding affinity than hits that are identified from HTS. Further modifications through organic synthesis into lead compounds are often required. Such modifications are often guided by protein X-ray crystallography of the protein-fragment complex. The advantages of these approaches are that they allow more efficient screening and the compound library, although small, typically covers

3840-802: The treatment of lung, breast, and ovarian cancer, as well as for Kaposi's sarcoma . Early in the 21st century, Cabazitaxel (made by Sanofi , a French firm), another relative of taxol has been shown effective against prostate cancer , also because it works by preventing the formation of microtubules, which pull the chromosomes apart in dividing cells (such as cancer cells). Other examples are: 1. Camptotheca ( Camptothecin · Topotecan · Irinotecan · Rubitecan · Belotecan ); 2. Podophyllum ( Etoposide · Teniposide ); 3a. Anthracyclines ( Aclarubicin · Daunorubicin · Doxorubicin · Epirubicin · Idarubicin · Amrubicin · Pirarubicin · Valrubicin · Zorubicin ); 3b. Anthracenediones ( Mitoxantrone · Pixantrone ). The second main approach involves ethnobotany ,

3904-513: The voluntary submission of well-documented, quality genomics data. Both agencies are considering the use of submitted data on a case-by-case basis for assessment purposes (e.g., to help elucidate mechanism of action or contribute to a weight-of-evidence approach) or for populating relevant comparative databases by encouraging parallel submissions of genomics data and traditional toxicological test results. Chemical Effects in Biological Systems

SECTION 60

#1733085285792

3968-414: Was Sir David Jack at Allen and Hanbury's, later Glaxo , who pioneered the first inhaled selective beta2-adrenergic agonist for asthma, the first inhaled steroid for asthma, ranitidine as a successor to cimetidine, and supported the development of the triptans. Gertrude Elion, working mostly with a group of fewer than 50 people on purine analogues, contributed to the discovery of the first anti-viral;

4032-560: Was a key technology enabling the efficient generation of large screening libraries for the needs of high-throughput screening. However, now, after two decades of combinatorial chemistry, it has been pointed out that despite the increased efficiency in chemical synthesis, no increase in lead or drug candidates has been reached. This has led to analysis of chemical characteristics of combinatorial chemistry products, compared to existing drugs or natural products. The chemoinformatics concept chemical diversity, depicted as distribution of compounds in

4096-568: Was driven by marketing strategies from vendor companies. The term is still not universally accepted, and others have offered alternative terms such as chemogenomics to describe essentially the same field of study. The nature and complexity of the data (in volume and variability) demands highly developed processes of automated handling and storage. The analysis usually involves a wide array of bioinformatics and statistics , often including statistical classification approaches. In pharmaceutical drug discovery and development , toxicogenomics

#791208